Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.

doi:10.3390/molecules26051417

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.

Molecules (Basel, Switzerland) - 5 Mar 2021

Telkoparan-Akillilar Pelin, Panieri Emiliano, Cevik Dilek, Suzen Sibel, Saso Luciano

Abstract excerpt

Cancer is one of the most fatal diseases with an increasing incidence and mortality all over the world. Thus, there is an urgent need for novel therapies targeting major cancer-related pathways. Nuclear factor-erythroid 2-related factor 2 (NRF2) and its major negative modulator Kelch-like ECH-associated protein 1 (KEAP1) are main players of the cellular defense mechanisms against internal and external cell...

Topics

Animals
Epigenesis, Genetic
Genes, Tumor Suppressor
Humans
Kelch-Like ECH-Associated Protein 1
Molecular Targeted Therapy
Mutation
NF-E2-Related Factor 2
Neoplasms
Oxidative Stress
Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 33808001
DOI: 10.3390/molecules26051417
PMCID: PMC7961421

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics